Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 27;10(4):775–781. doi: 10.1111/1759-7714.12998

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Treatment duration of nivolumab and ramucirumab (RAM) plus docetaxel (DTX) in all patients. Nine out of 20 patients experienced grade 3 adverse events. The treatment duration of nivolumab was < 90 days in 9 (75%) patients with a partial response (PR), 3 (50%) patients with stable disease (SD) and 2 (100%) patients with progressive disease (PD) on RAM + DTX. FN, febrile neutropenia; OS, overall survival; PTE, pulmonary thromboembolism. , Time receiving Nivolumab; , Time receiving DTX+RAM (PR Group); , Time receiving DTX+RAM (SD Group); , Time receiving DTX+RAM (PD Group) (dots DTX only); , OS not receiving DTX+RAM; , Progressive disease; , Adverse event, ≧Grade3; , Alive as of database lock.

Inline graphic — Treatment duration of nivolumab and ramucirumab (RAM) plus docetaxel (DTX) in all patients. Nine out of 20 patients experienced grade 3 adverse events. The treatment duration of nivolumab was < 90 days in 9 (75%) patients with a partial response (PR), 3 (50%) patients with stable disease (SD) and 2 (100%) patients with progressive disease (PD) on RAM + DTX. FN, febrile neutropenia; OS, overall survival; PTE, pulmonary thromboembolism. , Time receiving Nivolumab; , Time receiving DTX+RAM (PR Group); , Time receiving DTX+RAM (SD Group); , Time receiving DTX+RAM (PD Group) (dots DTX only); , OS not receiving DTX+RAM; , Progressive disease; , Adverse event, ≧Grade3; , Alive as of database lock.